NINDS.NIH.GOV : www.ninds.nih.gov - 37 in TOP 100 MEDICAL SITES. Rating: 135000.

Most popular searches: wwwninds.nih.gov, physician, blood pressure, drug rehab, medicine, www.ninds.nhi.gov, www.nidns.nih.gov, www.ninds.nih.gvo, www.nids.nih.gov, www.nins.nih.gov, www.ninds.ih.gov, health, www.innds.nih.gov, www.ninds.ni.gov, www.ninds.nih.gvo, medical research, www.ninds.nih.gv, Immunology, cholesterol, wwwninds.nih.gov, Nachrichten, www.ninsd.nih.gov, www.ninds.nih.ogv, patient, vaccines, www.ninds.nh.gov, www.nind.nih.gov, health care, medical information, www.nindsnih.gov, www.nnds.nih.gov, www.inds.nih.gov, genome, www.ninds.nih.com, www.nindsn.ih.gov, Pharmaceutical, asthma, www.ninds.nihgov, ww.ninds.nih.gov, Cardiac, www.ninds.nih.ov, ww.wninds.nih.gov, doctor, family practice, www.nind.snih.gov, www.ninds.ni.hgov, wwwn.inds.nih.gov, www.ninds.nih.gov, Krankenhaus, drug, obesity, Allergy, ww.ninds.nih.gov, www.ninds.nih.gov, www.ninds.inh.gov, www.ninds.nihg.ov, www.ninds.nih.go, www.nnids.nih.gov

What's Really in Supplements?
Dietary supplements have long raised safety worries and some doctors continue to be concerned about evidence of side effects from such herbal ingredients.
online.barrons.com

EU Court Orders Review of Glaxo Case
Europe's highest court said regulators need to give greater consideration to a plea by U.K. drug maker GlaxoSmithKline that it be exempted from normal competition rules in its efforts to curb wholesalers known as "parallel traders."
online.barrons.com

Dyax Corp. Q3 2009 Earnings Call Transcript
Dyax Corp. (DYAX)Q3 2009 Earnings CallOctober 28, 2009 10:00 am ETComplete Story »
seekingalpha.com

Nicorette Makes Quitting "Suck Less" - Video
Nicorette connects with smokers by using their own terms
feedproxy.google.com

Will Generex Biotech Be Next to Join the Winner's Circle?
This past year, small cap biotech investors were witness to some of the most profitable gains ever recorded. The only way to encapsulate it would be through two simple words, “FDA Approval”. Yes, any company with high probability of approval on their blockbuster drugs saw their shares literally explode beyond technical analysis comprehension.Companies like Dendreon Corporation (NASDAQ: DNDN), Human Genome Sciences (NASDAQ: HGSI), and MannKind Corporation (NASDAQ: MNKD) went from relatively unknown bench warmers to being the MVP trades of the year, having their share prices gain multi-hundred percentages while leaving investors hungry, salivating for the next candidate. Many tried, yet only a few succeeded to truly join the winner's circle.Complete Story »
seekingalpha.com